Oxeia Biopharmaceuticals

Oxeia Biopharmaceuticals is a clinical-stage biotechnology company dedicated to developing novel and innovative therapies for mild traumatic brain injury (mTBI), commonly known as concussion, and related neurometabolic dysfunction. The company has a drug named OXE-103, which will enter Phase 2 clinical trials in the fall of 2020. To date, no other studies have been conducted for these patients.